Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acyw135 meningococcal conjugate vaccine crm197
- Development stage
- Phase 4
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent, polysaccharide-protein conjugate vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. The vaccine uses purified oligosaccharides from these four serogroups, each covalently linked to a nontoxic mutant of diphtheria toxin called CRM197 as a carrier protein. This conjugation induces robust T-cell dependent immune responses, leading to long-lasting serogroup-specific, high-affinity IgG and mucosal immunity. Menhycia is the first of its kind in China, developed by CanSino Biologics, with evidence for safety and immunogenicity, intended for use in children as young as 3 months and up. The vaccine does not contain preservatives or animal-derived components and is administered by intramuscular injection[1][3][6].
- Brand names
- Menhycia
- Other names
- group acyw135 meningococcal conjugate vaccine crm197acyw135 群脑膜炎球菌多糖结合疫苗 crm197 载体quadrivalent meningococcal conjugate vaccine crm197
02
Targets
Neisseria meningitidis capsular polysaccharide
Beyond the preview
Go deeper on acyw135 meningococcal conjugate vaccine crm197.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acyw135 meningococcal conjugate vaccine crm197.